Efficacy and Safety of Empagliflozin in Type 1 Diabetes Mellitus Patients: A Systematic Review

被引：1
作者：
Saha, Sumanta [1 ]
Saha, Sujata [2 ]
机构：
[1] RG Kar Med Coll, Kolkata, W Bengal, India
[2] Mankar Coll, Mankar, W Bengal, India
来源：
TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2021年 / 25卷 / 04期
关键词：
Empagliflozin; sodium-glucose transporter 2 inhibitors; Type 1 diabetes mellitus; treatment outcome; adverse effects; SGLT2; INHIBITORS; INSULIN; METAANALYSIS; PLACEBO; DISEASE;
D O I：
10.25179/tjem.2021-83912
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
As the efficacy and safety of empagliflozin remain poorly studied in Type 1 diabetes mellitus (T1DM) patients, this narrative-systematic review aims to review it. The randomized controlled trials studying the above across different empagliflozin dosages and placebo got searched in PubMed, Embase, and Scopus databases. The database searches yielded 5 eligible trials reporting data of about 1,870 T1DM patients from 45 countries. The empagliflozin dosages tested in these trials were 2.5, 10, and 25 mg. The trials collectively showed a low or unclear risk of bias (Cochrane tool used). The existing double-blinded randomized controlled trials mainly suggest a dose-dependent decrease in glycated hemoglobin, body weight, and total weekly insulin requirement in empagliflozin-treated T1DM patients. Ketoacidosis, urinary tract infection, and study discontinuation due to side effects were rare adverse effects of empagliflozin. Genital infection predominantly occurred among recipients of 10 or 25 mg empagliflozin.
引用
收藏
页码：426 / 438
页数：13
相关论文
共 45 条
[1]   SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management? [J].
Ahmed-Sarwar, Nabila ;
Nagel, Angela K. ;
Leistman, Samantha ;
Heacock, Kevin .
ANNALS OF PHARMACOTHERAPY, 2017, 51 (09) :791-796
[2]   SGLT inhibition: a possible adjunctive treatment for type 1 diabetes [J].
Akturk, Halis Kaan ;
Rewers, Amanda ;
Garg, Satish K. .
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2018, 25 (04) :246-250
[3]   Glycemic Targets: Standards of Medical Care in Diabetes-2018 [J].
不详 .
DIABETES CARE, 2018, 41 :S55-S64
[4]  
[Anonymous], 2019, HIGHL PRESCR INF
[5]   Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials [J].
Boeder, Schafer ;
Edelman, Steven V. .
DIABETES OBESITY & METABOLISM, 2019, 21 :62-77
[6]   The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis [J].
Chen, Jiao ;
Fan, Fang ;
Wang, J. Y. ;
Long, Yang ;
Gao, C. L. ;
Stanton, R. C. ;
Xu, Yong .
SCIENTIFIC REPORTS, 2017, 7
[7]   The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus [J].
Cherney, David Z. I. ;
Perkins, Bruce A. ;
Soleymanlou, Nima ;
Har, Ronnie ;
Fagan, Nora ;
Johansen, Odd Erik ;
Woerle, Hans-Juergen ;
von Eynatten, Maximilian ;
Broedl, Uli C. .
CARDIOVASCULAR DIABETOLOGY, 2014, 13
[8]   SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence [J].
Davidson, Jaime A. .
POSTGRADUATE MEDICINE, 2019, 131 (04) :251-260
[9]   Sodium glucose cotransporters inhibitors in type 1 diabetes [J].
Dellepiane, Sergio ;
Ben Nasr, Moufida ;
Assi, Emma ;
Usuelli, Vera ;
Letizia, Teresa ;
D'Addio, Francesca ;
Zuccotti, Gian Vincenzo ;
Fiorina, Paolo .
PHARMACOLOGICAL RESEARCH, 2018, 133 :1-8
[10]   Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis [J].
El Masri, Dana ;
Ghosh, Samiran ;
Jaber, Linda A. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 137 :83-92
12345